Taysha: Applying AAV9 across the CNS
Taysha is leveraging the experience of former AveXis executives to develop AAV9 gene therapies
Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders.
The company spun out of the University of Texas Southwestern Medical Center with a pipeline of 15 gene therapy programs, an option to four more and an ongoing partnership with UT Southwestern.
CEO R.A. Session II told BioCentury the focus of those 19 initial programs is